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based cross sectional analysis. European Quality of Life scale (EQ-5D) was used for
assessment of HRQoL. Registered Hepatitis B patients aging 18 years and above
were approached. Descriptive statistics were used to describe demographic and
disease related characteristics of the patients. Percentages and frequencies were
used to categorize the categorical variables, while means and standard deviations
were calculated for the continuous variables. Non paramatric tests (Mann-Whitney
and Kruskal Wallis test) were used where appropriate. HRQoL was scored by using
values from UK general population survey. All analyses were performed using SPSS
16.0. RESULTS: Three hundred ninety hepatitis B Patients were enrolled in the
study with 232 (59.5%) of males. Majority (n126, 32.3%) were categorized in age
group of 18-30 years. HRQoL was measured poor in our study patients (0.3498
0.31785) with Visual Analogue Scale score of 59.1510.517. Among all variables,
only gender had significant relation with HRQoL score. CONCLUSIONS: Hepatitis B
has an adverse impact of on patients’ well-being and HRQoL. Patient centric efforts
are recommended to improve patients HRQoL with Hepatitis B.
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OBJECTIVES: The aim of this study was to estimate the impact on HRQL of in- and
outpatients with confirmed Influenza A H1N1/2009, and estimate the associated
burden during the pandemic season 2009-2010. METHODS: Longitudinal, observa-
tional, multi-centre study of in- and outpatients with confirmed diagnosis of influ-
enza A H1N1/2009 in Spain. Baseline sociodemographic and clinical characteristics
and HRQL were assessed at the hospitalization or primary care visit recruitment.
HRQL in the previous 7 days was also assessed. A sub-sample of patients was
followed-up after recovery. The EQ-5D was used to describe HRQL and calculate
utilities. HRQL loss was evaluated among in- and outpatients by several character-
istics. Loss of Quality Adjusted Life Years (QALYs) was calculated at individual level
taking into account the length of the influenza syndrome. Global burden was esti-
mated from the total number of cases in Spain. RESULTS: A total of 432 inpatients
and 563 outpatients were included and 145 and 184, respectively, were followed-
up. EQ-5D index previous to influenza was 0.81 (CI95% 0.78–0.84) for inpatients and
0.93 (CI95% 0.91–0.94) for outpatients. During influenza, HRQL loss was -0.58(0.02)
for inpatients, and -0.43(0.02) for outpatients. For all patients, Pain/discomfort and
Usual Activities were the most affected dimensions presenting a deterioration
from 73% to 80%. The individual QALYs loss for inpatients was 0.0135 and for
outpatients, 0.0098. In contrasts, the global burden was 41 (inpatients) and 7,283
QALYs (outpatients). CONCLUSIONS: Influenza H1N1/2009 supposed a significant,
but transient, impact on patients HRQL. The pandemic produced a considerable
QALYs loss, especially among less severe patients, comparable with the burden of
some chronic diseases and higher than that of other infectious diseases.
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OBJECTIVES:There is growing evidence in the literature supporting the association
between tobacco smoking and poor tuberculosis (TB) treatment outcomes. Con-
necting TB and tobacco cessation interventions has been strongly advocated as this
may produce significant benefits. However, no study has documented the impact
of such integration on health-related quality of life (HRQoL). The objective of the
study was to document the impact of an integrated TB directly observed therapy
short-course (DOTS) plus smoking cessation intervention (SCI) on HRQoL.
METHODS: This was a non-randomized controlled study (quasi experimental de-
sign) involving 120 TB patients who were current smokers at the time of TB diag-
nosis. Patients were assigned to either of two groups: conventional TB-DOTS plus
smoking cessation intervention (SCIDOTS group) or conventional TB-DOTS only
(DOTS group). The effects of the novel intervention on HRQoL were measured using
EQ-5D questionnaire. Two-way repeated measure ANOVA was used to examine
the effects. RESULTS: When compared, participants who received the integrated
intervention had a better HRQoL than those who received the conventional TB care.
The SCIDOTS group had a significantly greater increase in EQ-5D utility score than
the DOTS group during 6 months follow-up (mean SD 0.98 0.08 vs. 0.91 0.14,
p  0.006). Similarly, the mean scores for EQ-VAS showed a consistently similar
trend as the EQ-5D indices, with the scores increasing over the course of TB treat-
ment. Furthermore, for the EQ-VAS, there were significant main effects for group [F
(1, 84)  4.91, p  0.029, 2  0.06], time [F (2, 168)  139.50, p  0.001, 2  0.62]
and group x time interaction [F (2, 168)  13.89, p  0.001, 2  0.14].
CONCLUSIONS: This study provides evidence that an integrated TB-tobacco treat-
ment strategy could potentially improve overall quality of life outcomes among TB
patients who are smokers.
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OBJECTIVES: Health-related quality of life (HRQL) is modulated by the type and
frequency of symptoms experienced in daily life. Such a relationship is likely de-
termined in part by treatment regimen and health care system. We studied how
symptoms reported by HIV patients under PI- vs. NNTI-based HAART relate to
different HRQL dimensions on the PROQOL-HIV questionnaire. METHODS: N424
HAART patients (4110 yrs., 36% females, 8 countries), without comorbidity, com-
pleted a 31-symptom HIV checklist (presence/absence) and the PROQOL-HIV ques-
tionnaire (43 Likert items, 8 dimensions). Hierarchical cluster analysis uncovered
the structure of symptoms experienced in patients under PI (N242) or NNTI
(N182) regimen. Canonical correlation analysis (CCA) showed the relationships
between symptoms and HRQL dimensions, and between-country variations.
RESULTS: A common group of symptoms related to body fat (lipodystrophy) and
weight changes was shared by patients across treatment regimens. However, fre-
quency of some side-effects–sleep disturbance, headache, diarrhea, nausea, fa-
tigue and pain–were more frequent with PI regimens. The CCA showed that a) body
fat change, sleep disturbance, skin problems and abdominal pain symptoms were
related to the ‘body change’ and ‘physical health and symptoms’ HRQL dimensions
(canonical correlation, 0.78), and b) symptoms concerning physical appearance
were related to the ‘stigma’ dimension, whereas other side-effects did not. It also
replicated a common finding whereby patients from Western countries (France,
Australia, USA) tend to report better HRQL compared to Chinese and Cambodian
patients, the latter also experiencing more symptoms due to IP-based treatment.
CONCLUSIONS: Treatment-related symptoms aligned with PROQOL-HIV dimen-
sions and known differences between countries. The use of CCA as an exploratory
multiple endpoints model helped to unravel complex relationships between symp-
toms and HRQL facets. The choice of treatment strategies should rely not only on
symptoms experience, but also account for their relations to HRQL in light of vary-
ing access to care.
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OBJECTIVES:New protease inhibitors (PIs) significantly improve sustained virolog-
ical responses (SVRs) in patients with genotype 1 chronic hepatitis C. However,
treatment (Tx) in prior null-responders with advanced fibrosis often results in
failure to achieve SVR and development of resistant mutations. Emerging quadru-
ple Tx adding two direct antiviral agents may achieve SVR in nearly all of these
patients. This study aimed to compare two strategies: 1) treating prior null-re-
sponders with fibrosis stage 3 (F3) or stage 4 (F4) with telaprevir  peginterferon 
ribavirin (“TPR strategy”) versus 2) withholding Tx until more effective antiviral
agents become available (“Wait strategy”). METHODS: The MONARCH Hepatitis C
cost-effectiveness model was used to project outcomes in cohorts of 55-year-old
prior null-responders using published dynamic transition rates for disease pro-
gression. “TPR strategy” achieves SVR in 42% of F3 and in 14% of F4 patients. In
the Wait strategy, patients would wait for 5 years and then initiate quadruple Tx
yielding 90% SVR. Quadruple Tx would be used as rescue in patients failing
“TPR”, 70% of whom would harbor virus resistant to PIs. Patient outcome in
terms of SVR and quality-adjusted-life years (QALYs) were assessed 10 years there-
after. Benefits were discounted at 3.5%. RESULTS: Projected SVR rates were higher
with the “Wait strategy” (76% and 65% for F3 and F4 respectively) than “TPR
strategy” (50% and 30% for F3 and F4 respectively). Per-patient expected QALYs
were higher for “Wait strategy” than “TPR strategy”; 8.59 versus 8.47 QALYs in
F3 patients and 7.5 versus 6.7 QALYs in F4 patients. The Wait strategy was asso-
ciated with one-third fewer re-treatments. CONCLUSIONS:Waiting for future qua-
druple antiviral therapy maximized the predicted health benefit both in terms of
response (SVR) and QALYs; furthermore, the reduction in re-treatments associated
with the Wait strategy is noteworthy given the likely high cost of triple therapy.
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OBJECTIVES: To investigate the optimal pertussis booster vaccination strategy for
the The Netherlands and to explore the impact of different assumptions for pa-
rameters surrounded by uncertainty. METHODS: The authors designed a realistic
age-structured deterministic model. Assuming a steady state situation and cor-
recting for underreporting, the model was calibrated using notification data from
the period 1996-2000. Several sensitivity analyses were performed including vary-
ing the age of a booster dose (or multiple booster doses), expected vaccine uptake,
duration of protection after natural infection, underreporting factors, contact func-
tion, and transmission probabilities. RESULTS: The results indicated that the op-
timal age of an additional booster dose is in the range of 10-15 years, and imple-
mentation of this booster dose will reduce both symptomatic and asymptomatic
A283V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
